Article information
Summary
Presentamos un caso de cistadenocarcinoma seroso de ovario bilateral en una mujer de 62 años, tratada durante casi 7 años con terapia hormonal sustitutiva de la menopausia. Discutimos el estado del problema en la actualidad.
Summary
We present the case of a patient with bilateral ovarian serous cystadenocarcinoma in a 62 year old woman, who was treated for almost 7 years with HRT during the menopause. We discuss the present state of the problem.
Full text is only aviable in PDF
Bibliografía
[1.]
L. Speroff.
Tratamiento hormonal sustitutivo postmenopáusico: algunas preguntas frecuentes e infrecuentes (efecto de los estrógenos sobre el riesgo de cáncer de ovario.
THS: guía del prescriptor, pp. 44-45
[2.]
F Parazzini, Vecchia C La, E Negri, A. Villa.
Estrogen replacement therapy and ovarian cancer risk [carta].
Int J Cancer, 57 (1994), pp. 135-136
[3.]
P Hartge, R Hoover, L McGowan, L Lesher, HJ. Norris.
Menopause and ovarian cancer.
Am J Epidemiol, 127 (1988), pp. 990-998
[4.]
HO Adami, I Persson, R Hoover, C Schairer, L. Bergkvist.
Risk of cancer in women receiving hormone replacement therapy.
Int J Cancer, 44 (1989), pp. 833-839
[5.]
AS Whitemore, D Harris.
Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancer in white women.
Am J Epidemiol, 136 (1992), pp. 1184-1203
[6.]
C Rodríguez, EE Calle, RJ Coates, Mc Miracle, HL Mahill, MJ Thun, ClW Heath.
Jr Estrogen replacement therapy and fatal ovarian cancer.
Am J Epidemiol, 141 (1995), pp. 822-835
[7.]
I Persson, J Yuen, L Bergkvist, C. Schairer.
Cancer incidence and mortality in women receiving estrogen and estrogenprogestin replacement therapy. Long-term follow-up of a swedish cohort.
Int J Cancer, 67 (1996), pp. 327-332
[8.]
RE Hempling, CH Wong, S Piver, N Natarajan, CJ. Mettlin.
Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study.
Obstet Gynecol, 89 (1997), pp. 1012-1016
[9.]
CW Burger, P. Kenemans.
Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast.
Curr Opin Obstet Gynecol, 10 (1998), pp. 41-45
[10.]
PP Garg, K Kerlikowske, L Subak, D. Grady.
Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis.
Obstet Gynecol, 92 (1998), pp. 472-479
[11.]
DM Purdie, CJ Bain, V Siskind, P Russell, NF Hacker, et al.
Hormone replacement therapy and risk of epithelial ovarian cancer.
Br J Cancer, 81 (1999), pp. 559-563
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
